Literature DB >> 25797348

IgG subclass specificity to C1q determined by surface plasmon resonance using Protein L capture technique.

Rekha Patel1, Alyssa Neill2, Hongcheng Liu2, Bruce Andrien2.   

Abstract

Recombinant monoclonal antibodies (mAbs) have become an important category of biological therapeutics. mAbs share the same structures and biological functions as endogenous IgG molecules. One function is complement-dependent cytotoxicity (CDC) initiation by binding of C1q. Traditionally, ELISA methods have been utilized to measure C1q binding. A new robust capture method was established in this study to measure the binding affinity of C1q to antibodies by surface plasmon resonance (SPR). The utility of this method was demonstrated by determination of the difference in IgG subclass specificity of C1q binding.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C1q; Complement dependent cytotoxicity; Monoclonal antibodies; Surface plasmon resonance

Mesh:

Substances:

Year:  2015        PMID: 25797348     DOI: 10.1016/j.ab.2015.03.012

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

Review 1.  Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review.

Authors:  Rozaleen Dash; Sumit Kumar Singh; Narendra Chirmule; Anurag S Rathore
Journal:  AAPS J       Date:  2021-12-20       Impact factor: 4.009

2.  Biophysical Characterization of the Oligomeric States of Recombinant Immunoglobulins Type-M and Their C1q-Binding Kinetics by Biolayer Interferometry.

Authors:  Anne Chouquet; Andrea J Pinto; Julia Hennicke; Wai Li Ling; Isabelle Bally; Linda Schwaigerlehner; Nicole M Thielens; Renate Kunert; Jean-Baptiste Reiser
Journal:  Front Bioeng Biotechnol       Date:  2022-05-24

3.  Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study.

Authors:  Busra Gurel; Melike Berksoz; Eda Capkin; Ayhan Parlar; Meltem Corbacioglu Pala; Aylin Ozkan; Yılmaz Capan; Duygu Emine Daglikoca; Meral Yuce
Journal:  Pharmaceutics       Date:  2022-07-28       Impact factor: 6.525

4.  On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation.

Authors:  Joshua M Sopp; Shirley J Peters; Tania F Rowley; Robert J Oldham; Sonya James; Ian Mockridge; Ruth R French; Alison Turner; Stephen A Beers; David P Humphreys; Mark S Cragg
Journal:  Commun Biol       Date:  2021-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.